Cochrane · systematic review · CD008553
Prophylactic lidocaine for myocardial infarction
Martí-Carvajal, AJ, Simancas-Racines, D, Anand, V, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
HeartAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
58
current version
GRADE rated
35
No studies
23
Included studies
NR
No studies 23 · 39.7%Ungraded 0 · 0%Very low 31 · 53.4%Low 4 · 6.9%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Lidocaine compared with placebo or no intervention for acute myocardial infarction
Population: patients with acute myocardial infarction
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Lidocaine vs placebo or no intervention | RR 1.02 [0.85, 1.27] | 18 studies · 11727 participants | Low Downgraded: risk of bias |
Cardiac mortality Lidocaine vs placebo or no intervention | RR 1.03 [0.7, 1.5] | 12 studies · 8277 participants | Low Downgraded: risk of bias |
Overall survival at 30 days after myocardial infarction Lidocaine vs placebo or no intervention | no estimate extracted | NR | No studies |
Ventricular fibrillationElectrocardiogram Lidocaine vs placebo or no intervention | RR 0.78 [0.55, 1.12] | 16 studies · 10115 participants | Low Downgraded: risk of bias |
Adverse events (AEs; adverse drug reaction): asystole Lidocaine vs placebo or no intervention | RR 2.32 [1.26, 4.26] | 4 studies · 6826 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events (AEs; adverse drug reaction): sinus bradycardia Lidocaine vs placebo or no intervention | RR 1.09 [0.66, 1.8] | 8 studies · 2549 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events (AEs; adverse drug reaction): drowsiness/dizziness Lidocaine vs placebo or no intervention | RR 3.85 [2.29, 6.47] | 6 studies · 2533 participants | Low Downgraded: risk of bias, imprecision |
Lidocaine compared with disopyramide for myocardial infarction
Population: patients with myocardial infarction
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Lidocaine vs disopyramide | RR 1.39 [0.47, 4.13] | 2 studies · 144 participants | Very low Downgraded: risk of bias, imprecision |
Cardiac mortality Lidocaine vs disopyramide | RR 1.02 [0.21, 4.87] | 2 studies · 144 participants | Very low Downgraded: risk of bias, imprecision |
Overall survival at 30 days after myocardial infarction Lidocaine vs disopyramide | no estimate extracted | NR | No studies |
Ventricular fibrillation Lidocaine vs disopyramide | RR 0.32 [0.04, 2.97] | 1 study · 76 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events (AEs; adverse drug reaction): asystole Lidocaine vs disopyramide | RR 0.33 [0.01, 7.93] | 1 study · 76 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events (AEs; adverse drug reaction): sinoatrial block Lidocaine vs disopyramide | RR 0.94 [0.06, 14.47] | 1 study · 68 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events (AEs; adverse drug reaction): cardiac blocks (high‐degree atrioventricular block and bundle) Lidocaine vs disopyramide | RR 0.57 [0.15, 2.18] | 1 study · 68 participants | Very low Downgraded: imprecision |
Lidocaine compared with tocainide for myocardial infarction
Population: patients with myocardial infarction
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Lidocaine vs tocainide | RR 1.23 [0.08, 17.83] | 1 study · 29 participants | Very low Downgraded: risk of bias, imprecision |
Cardiac mortality Lidocaine vs tocainide | RR 1.23 [0.08, 17.83] | 1 study · 29 participants | Very low Downgraded: risk of bias, imprecision |
Overall survival at 30 days after myocardial infarction Lidocaine vs tocainide | no estimate extracted | NR | No studies |
Ventricular fibrillation Lidocaine vs tocainide | no estimate extracted | NR | No studies |
Adverse events (AEs; adverse drug reaction): any adverse event Lidocaine vs tocainide | RR 1.69 [1.07, 2.68] | 2 studies · 69 participants | Very low Downgraded: risk of bias, imprecision |
Lidocaine compared with mexiletine for myocardial infarction
Population: patients with myocardial infarction
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Lidocaine vs mexiletine | RR 0.33 [0.01, 7.45] | 1 study · 24 participants | Very low Downgraded: risk of bias, imprecision |
Cardiac mortality Lidocaine vs mexiletine | RR 0.33 [0.01, 7.45] | 1 study · 24 participants | Very low Downgraded: risk of bias, imprecision |
Overall survival at 30 days after myocardial infarction Lidocaine vs mexiletine | no estimate extracted | NR | No studies |
Ventricular fibrillation Lidocaine vs mexiletine | RR 3 [0.13, 67.06] | 1 study · 24 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events (AEs; adverse drug reaction): atrioventricular block Lidocaine vs mexiletine | RR 0.33 [0.01, 7.45] | 1 study · 24 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events (AEs; adverse drug reaction): composite neurological adverse event (confusion, vertigo, nystagmus, vomiting and diplopia) Lidocaine vs mexiletine | RR 0.63 [0.16, 2.47] | 2 studies · 74 participants | Very low Downgraded: risk of bias, imprecision |
Lidocaine compared with propafenone for myocardial infarction
Population: patients with myocardial infarction
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Lidocaine vs propafenone | no estimate extracted | NR | No studies |
Cardiac mortality Lidocaine vs propafenone | no estimate extracted | NR | No studies |
Overall survival at 30 days after myocardial infarction Lidocaine vs propafenone | no estimate extracted | NR | No studies |
Ventricular fibrillation Lidocaine vs propafenone | RR 3 [0.14, 65.9] | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events (AEs; adverse drug reaction): heart failure Lidocaine vs propafenone | RR 6.38 [0.32, 127.77] | 1 study · 64 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events (AEs; adverse drug reaction): bilateral bundle branch block Lidocaine vs propafenone | RR 0.43 [0.02, 10.06] | 1 study · 64 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events (AEs; adverse drug reaction): neuropsychiatric disturbances Lidocaine vs propafenone | RR 6.95 [0.86, 55.94] | 2 studies · 84 participants | Very low Downgraded: risk of bias, imprecision |
Lidocaine compared with amiodarone for myocardial infarction
Population: patients with myocardial infarction
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Lidocaine vs amiodarone | no estimate extracted | NR | No studies |
Cardiac mortality Lidocaine vs amiodarone | no estimate extracted | NR | No studies |
Overall survival at 30 days after myocardial infarction Lidocaine vs amiodarone | no estimate extracted | NR | No studies |
Ventricular fibrillation Lidocaine vs amiodarone | RR 3.44 [0.18, 46.11] | 1 study · 25 participants | Very low Downgraded: risk of bias, imprecision |
Bradycardia Lidocaine vs amiodarone | RR 0.23 [0.01, 5.12] | 1 study · 25 participants | Very low Downgraded: risk of bias, imprecision |
Hypotension Lidocaine vs amiodarone | RR 0.14 [0.01, 2.6] | 1 study · 25 participants | Very low Downgraded: risk of bias, imprecision |
Diplopia plus sleepiness Lidocaine vs amiodarone | RR 2.06 [0.09, 46.11] | 1 study · 25 participants | Very low Downgraded: risk of bias, imprecision |
Lidocaine compared with dimethylammonium for myocardial infarction
Population: patients with myocardial infarction
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Lidocaine vs dimethylammonium | no estimate extracted | NR | No studies |
Cardiac mortality Lidocaine vs dimethylammonium | no estimate extracted | NR | No studies |
Overall survival at 30 days after myocardial infarction Lidocaine vs dimethylammonium | no estimate extracted | NR | No studies |
Ventricular fibrillation Lidocaine vs dimethylammonium | no estimate extracted | NR | No studies |
Hypotension Lidocaine vs dimethylammonium | RR 0.85 [0.28, 2.59] | 1 study · 31 participants | Very low Downgraded: risk of bias, imprecision |
Tachycardia Lidocaine vs dimethylammonium | RR 0.06 [0, 1] | 1 study · 31 participants | Very low Downgraded: risk of bias, imprecision |
Bradycardia Lidocaine vs dimethylammonium | RR 0.35 [0.02, 8.08] | 1 study · 31 participants | Very low Downgraded: risk of bias, imprecision |
Lidocaine compared with aprindine for myocardial infarction
Population: patients with myocardial infarction
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Lidocaine vs aprindine | no estimate extracted | NR | No studies |
Cardiac mortality Lidocaine vs aprindine | no estimate extracted | NR | No studies |
Overall survival at 30 days after myocardial infarction Lidocaine vs aprindine | no estimate extracted | NR | No studies |
Ventricular fibrillation Lidocaine vs aprindine | no estimate extracted | NR | No studies |
Coma Lidocaine vs aprindine | RR 3 [0.13, 67.06] | 1 study · 24 participants | Very low Downgraded: risk of bias, imprecision |
Seizures Lidocaine vs aprindine | RR 5 [0.27, 94.34] | 1 study · 24 participants | Very low Downgraded: risk of bias, imprecision |
Agitation Lidocaine vs aprindine | RR 0.2 [0.01, 3.77] | 1 study · 24 participants | Very low Downgraded: risk of bias, imprecision |
Lidocaine compared with pirmenol for myocardial infarction
Population: patients with myocardial infarction
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Lidocaine vs pirmenol | no estimate extracted | NR | No studies |
Cardiac mortality Lidocaine vs pirmenol | no estimate extracted | NR | No studies |
Overall survival at 30 days after myocardial infarction Lidocaine vs pirmenol | no estimate extracted | NR | No studies |
Ventricular fibrillation Lidocaine vs pirmenol | no estimate extracted | NR | No studies |
Safety (AEs; adverse drug reaction): any adverse event Lidocaine vs pirmenol | RR 1.11 [0.47, 2.6] | 1 study · 19 participants | Very low Downgraded: risk of bias, imprecision |